Thoma B, Grell M, Pfizenmaier K, Scheurich P
Clinical Research Group, University of Göttingen, Federal Republic of Germany.
J Exp Med. 1990 Oct 1;172(4):1019-23. doi: 10.1084/jem.172.4.1019.
We describe here a monoclonal antibody (H398) that immunoprecipitates a human 60-kD tumor necrosis factor (TNF) membrane receptor (p60) and competes with TNF binding to p60 but not to p85 TNF receptors. Despite partial inhibition of TNF binding capacity of cells coexpressing both TNF receptor molecules, H398 uniformly and completely inhibits very distinct TNF responses on a variety of cell lines. These data suggest a limited structural heterogeneity in those components actually contributing to TNF responsiveness and identify p60 as a common receptor molecule essential for TNF signal transduction. As H398 is a highly effective TNF antagonist in vitro, it might be useful as a therapeutic agent in the treatment of TNF-mediated acute toxicity.
我们在此描述一种单克隆抗体(H398),它能免疫沉淀一种人类60-kD肿瘤坏死因子(TNF)膜受体(p60),并与TNF竞争结合p60,但不与p85 TNF受体结合。尽管共表达两种TNF受体分子的细胞的TNF结合能力受到部分抑制,但H398能均匀且完全抑制多种细胞系上非常不同的TNF反应。这些数据表明,在实际促成TNF反应性的那些成分中存在有限的结构异质性,并确定p60是TNF信号转导所必需的共同受体分子。由于H398在体外是一种高效的TNF拮抗剂,它可能作为治疗TNF介导的急性毒性的治疗剂而有用。